PTC518 for Huntington's Disease

Recruiting in Palo Alto (17 mi)

+25 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: PTC Therapeutics

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of PTC518 in participants with HD.

Eligibility Criteria

This trial is specifically for individuals who have Huntington's Disease and have already completed the treatment period in a prior study, PTC518-CNS-002-HD. It's not open to those who haven't participated in that initial study.

Participant Groups

The focus of this extension study is on assessing the long-term safety and effectiveness of a drug called PTC518 for people with Huntington's Disease who were previously involved in an earlier phase of research.

3Treatment groups

Experimental Treatment

Group I: PTC518 5 mgExperimental Treatment1 Intervention

Participants will receive PTC518 5 mg tablets once daily orally for 24 months.

Group II: PTC518 20 mgExperimental Treatment1 Intervention

Participants will receive PTC518 20 mg tablets once daily orally for 24 months.

Group III: PTC518 10 mgExperimental Treatment1 Intervention

Participants will receive PTC518 10 mg tablets once daily orally for 24 months.